Brain Drug Discovery Summit
Introducing the Brain Drug Discovery Summit
The 2026 Drug Discovery Summit is a two-day professional-only conference co-located alongside Naidex, Care & Dementia and Neuro Rehab and is an opportunity for anyone involved with drug development and clinical trials. In addition to Alzheimer’s drug research, the event will include other neurological conditions such as Parkinson's, Multiple Sclerosis, MND and Lewy body.
With a focus on unravelling disease mechanisms and improving treatment for Alzheimer's, Parkinson's, and other neurodegenerative disorders, this event hopes to contribute to accelerating the development of new treatments and ultimately, translating ground-breaking discoveries into effective treatments that can improve the lives of those affected by these debilitating conditions.
Pre-registration will open shortly.
The 2026 Summit follows on from the inaugural one-day Alzheimer's Drug Discovery Summit, sponsored by TauRx, Eisai, Luye Pharma and Re:Cognition Health held in 2024, which was a highly successful gathering, equipping primary and community care professionals with the latest information in Alzheimer's research and treatment.
Chaired by Professor Fiona Ducotterd, Chief Scientific Officer at Alzheimer's Research UK, the summit featured prominent speakers like Dr. Emer MacSweeney on PET biomarkers and Dr. Amanda Heslegrave on fluid biomarkers, alongside a GP Panel addressing challenges in discussing treatment options.
The event highlighted the critical role of early detection and the rapid advancements in diagnostics and therapeutics, providing attendees with practical tools and insights to better inform their patients.
Who attends
){kind=logo}
)
)
)
)
){kind=logo}
){kind=logo}
)